A Phase 1b study for Vertex's VX-985 protease inhibitor for HCV is now enrolling. "A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study of VX-985 in Subjects With Genotype 1 Chronic Hepatitis C. "
The purpose of this study it to evaluate the safety and tolerability of VX-985 in HCV subjects. This study will also evaluate the antiviral activity and pharmacokinetic profile of VX-985.
More info here: http://www.clinicaltrials.gov/ct2/show/NCT01144936?term=Hepatitis+C&lup_s=07%2F01%2F2010&lup_e=07%2F15%2F2010&rank=36
Subscribe to:
Post Comments (Atom)
Posts
No comments:
Post a Comment